Literature DB >> 18509009

Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.

L Cerquetti1, B Bucci, R Marchese, S Misiti, U De Paula, R Miceli, A Muleti, D Amendola, P Piergrossi, E Brunetti, V Toscano, A Stigliano.   

Abstract

Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) is an agent with adrenotoxic effect, which is able to block cortisol synthesis. This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown. We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells. Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination. This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells. Cell cycle analysis showed that IR alone and IR/o,p'-DDD in combination induced the cell accumulation in the G2 phase. At 120 h after IR, the cells were able to recover the IR-induced G2 block while cells treated with IR/o,p'-DDD were still arrested in G2 phase. In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest. In these cells, cyclin B1 and Cdk2 proteins were examined by western blot and Cdk2 kinase activity measured by assay kit. The H295R cells treated with IR/o,p'-DDD shared an increase in cyclin B1 amount as the coimmunoprecipitation of Cdc2-cyclin B1 complex. The kinase activity also shows an increase in the treated cells with combination therapy. Moreover, in these cells, sequence analysis of p53 revealed a large deletion of exons 8 and 9. The same irreversible block on G2 phase, induced by IR/o,p'-DDD treatment, happened in H295R cells with restored wild-type p53 suggesting that this mechanism is not mediated by p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509009     DOI: 10.1677/erc.1.1315

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  16 in total

1.  Contemporary preclinical human models of adrenocortical carcinoma.

Authors:  Emilia Modolo Pinto; Katja Kiseljak-Vassiliades; Constanze Hantel
Journal:  Curr Opin Endocr Metab Res       Date:  2019-08-29

Review 2.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

4.  New strategies for applying targeted therapies to adrenocortical carcinoma.

Authors:  Dipika R Mohan; Antonio Marcondes Lerario; Isabella Finco; Gary D Hammer
Journal:  Curr Opin Endocr Metab Res       Date:  2019-08-06

5.  Therapy of adrenocortical cancer: present and future.

Authors:  Daniela F Maluf; Brás H de Oliveira; Enzo Lalli
Journal:  Am J Cancer Res       Date:  2010-12-07       Impact factor: 6.166

Review 6.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

7.  Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer.

Authors:  Vince Kornél Grolmusz; Katalin Karászi; Tamás Micsik; Eszter Angéla Tóth; Katalin Mészáros; Gellért Karvaly; Gábor Barna; Péter Márton Szabó; Kornélia Baghy; János Matkó; Ilona Kovalszky; Miklós Tóth; Károly Rácz; Péter Igaz; Attila Patócs
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

8.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

9.  p53 Stabilization induces cell growth inhibition and affects IGF2 pathway in response to radiotherapy in adrenocortical cancer cells.

Authors:  Camilla Sampaoli; Lidia Cerquetti; Randa El Gawhary; Barbara Bucci; Donatella Amendola; Rodolfo Marchese; Silvia Misiti; Giuseppe Novelli; Vincenzo Toscano; Antonio Stigliano
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.

Authors:  Marine Guillaud-Bataille; Bruno Ragazzon; Aurélien de Reyniès; Claire Chevalier; Isabelle Francillard; Olivia Barreau; Virginie Steunou; Johann Guillemot; Frédérique Tissier; Marthe Rizk-Rabin; Fernande René-Corail; Abir Al Ghuzlan; Guillaume Assié; Xavier Bertagna; Eric Baudin; Yves Le Bouc; Jérôme Bertherat; Eric Clauser
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.